Advertisement

Journal of Computer-Aided Molecular Design

, Volume 29, Issue 1, pp 37–46 | Cite as

Molecular dynamics simulation of halogen bonding mimics experimental data for cathepsin L inhibition

  • Cristian Celis-Barros
  • Leslie Saavedra-Rivas
  • J. Cristian Salgado
  • Bruce K. Cassels
  • Gerald Zapata-TorresEmail author
Article

Abstract

A MD simulation protocol was developed to model halogen bonding in protein–ligand complexes by inclusion of a charged extra point to represent the anisotropic distribution of charge on the halogen atom. This protocol was then used to simulate the interactions of cathepsin L with a series of halogenated and non-halogenated inhibitors. Our results show that chloro, bromo and iodo derivatives have progressively narrower distributions of calculated geometries, which reflects the order of affinity I > Br > Cl, in agreement with the IC50 values. Graphs for the Cl, Br and I analogs show stable interactions between the halogen atom and the Gly61 carbonyl oxygen of the enzyme. The halogen-oxygen distance is close to or less than the sum of the van der Waals radii; the C–X···O angle is about 170°; and the X···O=C angle approaches 120°, as expected for halogen bond formation. In the case of the iodo-substituted analogs, these effects are enhanced by introduction of a fluorine atom on the inhibitors’ halogen-bonding phenyl ring, indicating that the electron withdrawing group enlarges the σ-hole, resulting in improved halogen bonding properties.

Keywords

Halogen bonding MD simulation Halogenated inhibitors Cathepsin L Interactions 

Notes

Acknowledgments

This study was supported by FONDECYT Grant 1110146.

Conflict of interest

The authors declare no competing financial interests.

Supplementary material

10822_2014_9802_MOESM1_ESM.doc (35.1 mb)
Supplementary material 1 (DOC 35971 kb)

References

  1. 1.
    Desiraju GR, Ho PS, Kloo L, Legon AC, Marquardt R, Metrangolo P, Politzer P, Resnati G, Rissanen K (2013) Definition of the halogen bond (IUPAC Recommendations 2013). Pure Appl Chem 85:1711–1713CrossRefGoogle Scholar
  2. 2.
    Politzer P, Lane P, Concha MC, Ma Y, Murray JS (2007) An overview of halogen bonding. J Mol Model 13:305–311CrossRefGoogle Scholar
  3. 3.
    Metrangolo P, Neukirch H, Pilati T, Resnati G (2005) Halogen bonding based recognition processes: a world parallel to hydrogen bonding. Acc Chem Res 38:386–395CrossRefGoogle Scholar
  4. 4.
    Clark T, Hennemann M, Murray J, Politzer P (2007) Halogen bonding: the σ-hole. J Mol Model 13:291–296CrossRefGoogle Scholar
  5. 5.
    Metrangolo P, Murray JS, Pilati T, Politzer P, Resnati G, Terraneo G (2011) The fluorine atom as a halogen bond donor, viz a positive site. Cryst Eng Comm 13:6593–6596CrossRefGoogle Scholar
  6. 6.
    Metrangolo P, Murray JS, Pilati T, Politzer P, Resnati G, Terraneo G (2011) Fluorine-centered halogen bonding: a factor in recognition phenomena and reactivity. Cryst Growth Des 11:4238–4246CrossRefGoogle Scholar
  7. 7.
    Wilcken R, Zimmermann MO, Lange A, Zahn S, Boeckler FM (2012) Using halogen bonds to address the protein backbone: a systematic evaluation. J Comput Aided Mol Des 26:935–945CrossRefGoogle Scholar
  8. 8.
    Politzer P, Murray JS, Concha MC (2007) Halogen bonding and the design of new materials: organic bromides, chlorides and perhaps even fluorides as donors. J Mol Model 13:643–650CrossRefGoogle Scholar
  9. 9.
    Metrangolo P, Resnati G (2008) Halogen bonding: fundamentals and applications. Springer, BerlinCrossRefGoogle Scholar
  10. 10.
    Scholfield MR, Zanden CMV, Carter M, Ho PS (2013) Halogen bonding (X-bonding): a biological perspective. Protein Sci 22:139–152CrossRefGoogle Scholar
  11. 11.
    Lu Y, Shi T, Wang Y, Yang H, Yan X, Luo X, Jiang H, Zhu W (2009) Halogen bonding—A novel interaction for rational drug design? J Med Chem 52:2854–2862CrossRefGoogle Scholar
  12. 12.
    Hardegger LA, Kuhn B, Spinnler B, Anselm L, Ecabert R, Stihle M, Gsell B, Thoma R, Diez J, Benz J, Plancher J-M, Hartmann G, Banner DW, Haap W, Diederich F (2011) Systematic investigation of halogen bonding in protein–ligand interactions. Angew Chem Int Ed 50:314–318CrossRefGoogle Scholar
  13. 13.
    Xu Z, Liu Z, Chen T, Chen T, Wang Z, Tian G, Shi J, Wang X, Lu Y, Yan X, Wang G, Jiang H, Chen K, Wang S, Xu Y, Shen J, Zhu W (2011) Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors. J Med Chem 54:5607–5611CrossRefGoogle Scholar
  14. 14.
    Wilcken R, Zimmermann MO, Lange A, Joerger AC, Boeckler FM (2013) principles and applications of halogen bonding in medicinal chemistry and chemical biology. J Med Chem 56:1363–1388CrossRefGoogle Scholar
  15. 15.
    Ibrahim MAA (2011) Molecular mechanical study of halogen bonding in drug discovery. J Comput Chem 32:2564–2574CrossRefGoogle Scholar
  16. 16.
    Rendine S, Pieraccini S, Forni A, Sironi M (2011) Halogen bonding in ligand-receptor systems in the framework of classical force fields. Phys Chem Chem Phys 13:19508–19516CrossRefGoogle Scholar
  17. 17.
    Kolář M, Hobza P (2012) On extension of the current biomolecular empirical force field for the description of halogen bonds. J Chem Theory Comput 8:1325–1333CrossRefGoogle Scholar
  18. 18.
    Jorgensen WL, Schyman P (2012) Treatment of halogen bonding in the OPLS-AA force field: application to potent anti-HIV agents. J Chem Theory Comput 8:3895–3901CrossRefGoogle Scholar
  19. 19.
    Carter M, Rappé AK, Ho PS (2012) Scalable anisotropic shape and electrostatic models for biological bromine halogen bonds. J Chem Theory Comput 8:2461–2473CrossRefGoogle Scholar
  20. 20.
    El Hage K, Piquemal J-P, Hobaika Z, Maroun RG, Gresh N (2013) Could an anisotropic molecular mechanics/dynamics potential account for sigma hole effects in the complexes of halogenated compounds? J Comput Chem 34:1125–1135CrossRefGoogle Scholar
  21. 21.
    Du L, Gao J, Bi F, Wang L, Liu C (2013) A polarizable ellipsoidal force field for halogen bonds. J Comput Chem 34:2032–2040CrossRefGoogle Scholar
  22. 22.
    Liu Y, Xu Z, Yang Z, Chen K, Zhu W (2013) A knowledge-based halogen bonding scoring function for predicting protein-ligand interactions. J Mol Model 19:5015–5030CrossRefGoogle Scholar
  23. 23.
    Hardegger LA, Kuhn B, Spinnler B, Anselm L, Ecabert R, Stihle M, Gsell B, Thoma R, Diez J, Benz J, Plancher J-M, Hartmann G, Isshiki Y, Morikami K, Shimma N, Haap W, Banner DW, Diederich F (2011) Halogen bonding at the active sites of human cathepsin L and MEK1 kinase: efficient interactions in different environments. ChemMedChem 6:2048–2054CrossRefGoogle Scholar
  24. 24.
    Debouck C, Metcalf B (2000) The impact of genomics on drug discovery. Annu Rev Pharmacol Toxicol 40:193–207CrossRefGoogle Scholar
  25. 25.
    Podgorski I (2009) Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem 1:21–34CrossRefGoogle Scholar
  26. 26.
    Huryn DM, Smith AB 3rd (2009) The identification, characterization and optimization of small molecule probes of cysteine proteases: experiences of the Penn Center for molecular discovery with cathepsin B and cathepsin L. Curr Top Med Chem 9:1206–1216CrossRefGoogle Scholar
  27. 27.
    Schröder J, Klinger L, Oellien F, Marhöfer RJ, Duszenko M, Selzer PM (2013) Docking-based virtual screening of covalently-binding ligands: an orthogonal lead discovery approach. J Med Chem 56:1478–1490CrossRefGoogle Scholar
  28. 28.
    Leto G, Sepporta MV, Crescimanno M, Flandina C, Tumminello FM (2010) Cathepsin L in metastatic bone disease: therapeutic implications. Biol Chem 391:655–664CrossRefGoogle Scholar
  29. 29.
    Lafarge JC, Naour N, Clément K, Guerre-Millo M (2010) Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie 92:1580–1586CrossRefGoogle Scholar
  30. 30.
    Reiser J, Adair B, Reinheckel T (2010) Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 120:3421–3431CrossRefGoogle Scholar
  31. 31.
    Hook V, Funkelstein L, Wegrzyn J, Bark S, Kindy M, Hook G (2012) Cysteine cathepsins in the secretory vesicle produce active peptides: cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer’s disease. Biochim Biophys Acta 1824:89–104CrossRefGoogle Scholar
  32. 32.
    Álvarez Sánchez R, Banner D, Ceccarelli SM, Grether U, Haap W, Hartman P, Hartmann G, Hilpert H, Kuehne H, Mauser H, Plancher J-M. (F. Hoffmann-La Roche A.G.), Novel Proline Derivatives. US20100267722 (A1), October 21, 2010Google Scholar
  33. 33.
    Riley KE, Murray JS, Fanfrlík J, Řezáč J, Solá RJ, Concha MC, Ramos FM, Politzer P (2011) Halogen bond tunability I: the effects of aromatic fluorine substitution on the strengths of halogen-bonding interactions involving chlorine, bromine, and iodine. J Mol Model 17:3309–3318CrossRefGoogle Scholar
  34. 34.
    Bondi A (1964) van der Waals volumes and radii. J Phys Chem 68:441–451CrossRefGoogle Scholar
  35. 35.
    Politzer P, Murray JS (2013) Enthalpy and entropy factors in gas phase halogen bonding: compensation and competition. Cryst Eng Comm 15:3145–3150CrossRefGoogle Scholar
  36. 36.
    Wilcken R, Zimmerman MO, Lange A, Zahn S, Kirchner B, Boeckler FM (2011) Addressing methionine in molecular design through directed sulphur-halogen bonds. J Chem Theory Comput 7:2307–2315CrossRefGoogle Scholar
  37. 37.
    Carter M, Voth AR, Scholfield MR, Rummel B, Sowers LC, Ho PS (2013) Enthalpy–entropy compensation in biomolecular halogen bonds measured in DNA junctions. Biochemistry 52:4891–4903CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Cristian Celis-Barros
    • 1
  • Leslie Saavedra-Rivas
    • 1
  • J. Cristian Salgado
    • 1
  • Bruce K. Cassels
    • 1
  • Gerald Zapata-Torres
    • 1
    Email author
  1. 1.University of ChileSantiagoChile

Personalised recommendations